Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease
{{output}}
The judicious use of surrogate endpoints as substitutes for patient relevant target outcomes can substantially reduce the size and duration of clinical trials, thereby driving down research and development costs and driving faster patient access to innovative ... ...
